{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:28:28Z","timestamp":1780374508823,"version":"3.54.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,1,29]],"date-time":"2014-01-29T00:00:00Z","timestamp":1390953600000},"content-version":"vor","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.jiac.2013.08.008","type":"journal-article","created":{"date-parts":[[2013,12,11]],"date-time":"2013-12-11T01:30:42Z","timestamp":1386725442000},"page":"1-5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Clinical practice guidelines for therapeutic drug monitoring of arbekacin: A consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring"],"prefix":"10.1016","volume":"20","author":[{"given":"Kenji","family":"Okada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshige","family":"Mikamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Kasahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Seki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Takakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issei","family":"Tokimatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Ohmagari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Nishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Tanigawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Takesue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2013.08.008_bib1","doi-asserted-by":"crossref","first-page":"412","DOI":"10.7164\/antibiotics.26.412","article-title":"Syntheses of 1-n-((S)-4-amino-2-hydroxybutyryl)-kanamycin B and -3\u2032,4\u2032-dideoxykanamycin B active against kanamycin-resistant bacteria","volume":"26","author":"Kondo","year":"1973","journal-title":"J\u00a0Antibiot"},{"key":"10.1016\/j.jiac.2013.08.008_bib2","first-page":"640","article-title":"Bactericidal activity of arbekacin against methicillin-resistant Staphylococcus aureus. Comparison with that of vancomycin","volume":"47","author":"Aoki","year":"1994","journal-title":"Jpn J Antibiot"},{"key":"10.1016\/j.jiac.2013.08.008_bib3","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/jac\/35.6.865","article-title":"Activity of the semi-synthetic kanamycin B derivative, arbekacin against methicillin-resistant Staphylococcus aureus","volume":"35","author":"Hamilton-Miller","year":"1995","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2013.08.008_bib4","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1128\/AAC.00480-05","article-title":"Pharmacokinetic-pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureus","volume":"50","author":"Sato","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.jiac.2013.08.008_bib5","doi-asserted-by":"crossref","first-page":"35S","DOI":"10.1111\/j.1365-2125.2001.00377.x","article-title":"The therapeutic monitoring of antimicrobial agents","volume":"52","author":"Begg","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jiac.2013.08.008_bib6","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/cpt1977213362","article-title":"Kinetic model for gentamicin dosing with the use of individual patient parameters","volume":"21","author":"Sawchuk","year":"1977","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jiac.2013.08.008_bib7","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1128\/AAC.41.5.1115","article-title":"Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing","volume":"41","author":"Demczar","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2013.08.008_bib8","first-page":"1193","article-title":"The periodic health examination","volume":"121","author":"Canadian Task Force on the Periodic Health Examination","year":"1979","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.jiac.2013.08.008_bib9","first-page":"18","article-title":"Pharmacokinetic and pharmacodynamic (PK-PD) analysis to determine the optimal method of arbekacin administration","volume":"54","author":"Kobayashi","year":"2006","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.jiac.2013.08.008_bib10","first-page":"55","article-title":"Postmarketing surveillance review of arbekacin sulfate in patients with therapeutic drug monitoring","volume":"27","author":"Kawano","year":"2010","journal-title":"Jpn J Ther Drug Monit"},{"key":"10.1016\/j.jiac.2013.08.008_bib11","first-page":"469","article-title":"Study of clinical significance of PK\/PD (pharmacokinetic\/pharmacodynamic) parameters after administering arbekacin to patients with pulmonary methicillin-resistant Staphylococcus aureus infection","volume":"52","author":"Tanikaze","year":"2004","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.jiac.2013.08.008_bib12","first-page":"299","article-title":"An open clinical study of arbekacin 200\u00a0mg q.d. in patients infected with methicillin-resistant Staphylococcus aureus (MRSA) \u2014 a clinical pharmacology study","volume":"56","author":"Aikawa","year":"2008","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.jiac.2013.08.008_bib13","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1128\/AAC.00420-05","article-title":"Population pharmacokinetics of arbekacin in patients infected with methicillin-resistant Staphylococcus aureus","volume":"50","author":"Tanigawara","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2013.08.008_bib14","doi-asserted-by":"crossref","first-page":"701","DOI":"10.5649\/jjphcs.35.701","article-title":"Factors influencing peak concentrations of arbekacin in patients","volume":"35","author":"Ikeda","year":"2009","journal-title":"Jpn J Pharm Health Care Sci"},{"key":"10.1016\/j.jiac.2013.08.008_bib15","first-page":"119","article-title":"Therapeutic drug monitoring survey of anti-MRSA agents in Japan","volume":"58","author":"Kobayashi","year":"2010","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.jiac.2013.08.008_bib16","first-page":"597","article-title":"Dose finding study on arbekacin sulfate for appropriate peak levels","volume":"59","author":"Kimura","year":"2011","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.jiac.2013.08.008_bib17","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s10156-012-0397-4","article-title":"The efficacy and safety of high-dose arbekacin sulfate therapy (once-daily treatment) in patients with MRSA infection","volume":"18","author":"Yamamoto","year":"2012","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.jiac.2013.08.008_bib18","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1046\/j.1442-200X.2003.01722.x","article-title":"Efficacy and safety of arbekacin for staphylococcal infection in the NICU","volume":"45","author":"Suzuki","year":"2003","journal-title":"Pediatr Int"},{"key":"10.1016\/j.jiac.2013.08.008_bib19","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s10156-012-0519-z","article-title":"Clinical efficacy and safety of arbekacin sulfate in patients with MRSA sepsis or pneumonia: a multi-institutional study","volume":"19","author":"Matsumoto","year":"2013","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.jiac.2013.08.008_bib20","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1128\/AAC.39.2.545","article-title":"Aminoglycoside dosing weight correction factors for patients of various body sizes","volume":"39","author":"Traynor","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2013.08.008_bib21","first-page":"98","article-title":"Population pharmacokinetic analysis of arbekacin sulfate in adult patients","volume":"27","author":"Sato","year":"2010","journal-title":"Jpn J Ther Drug Monit"},{"key":"10.1016\/j.jiac.2013.08.008_bib22","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1086\/600884","article-title":"Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients","volume":"49","author":"Lodise","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2013.08.008_bib23","first-page":"520","article-title":"Evaluation of initial dosage in neonates based on population pharmacokinetics of arbekacin","volume":"54","author":"Kimura","year":"2006","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.jiac.2013.08.008_bib24","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1128\/AAC.48.4.1159-1167.2004","article-title":"Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates","volume":"48","author":"Kimura","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2013.08.008_bib25","first-page":"727","article-title":"Evaluation of once a day of arbekacin administration to neonates as a new object of peak concentration","volume":"84","author":"Kinoshita","year":"2010","journal-title":"J\u00a0Jpn Assoc Infect Dis"},{"key":"10.1016\/j.jiac.2013.08.008_bib26","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1128\/AAC.24.2.246","article-title":"Gentamicin substrate-labeled fluorescent immunoassay containing monoclonal antibody","volume":"24","author":"Place","year":"1983","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl.\u00a0A","key":"10.1016\/j.jiac.2013.08.008_bib27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/jac\/8.suppl_A.27","article-title":"Inactivation of aminoglycosides by penicillins","volume":"8","author":"Farchione","year":"1981","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2013.08.008_bib28","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1128\/AAC.35.1.182","article-title":"In\u00a0vitro inactivation of aminoglycosides by sulbactam, other beta-lactams, and sulbactam-beta-lactam combinations","volume":"35","author":"Fuchs","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2013.08.008_bib29","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1128\/AAC.15.4.592","article-title":"Effect of time and concentration upon interaction between gentamicin, tobramycin, Netilmicin, or amikacin and carbenicillin or ticarcillin","volume":"15","author":"Pickering","year":"1979","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X13000342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X13000342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:49:51Z","timestamp":1761158991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X13000342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S1341321X13000342"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2013.08.008","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical practice guidelines for therapeutic drug monitoring of arbekacin: A consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2013.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}